Vortioxetine, a new multimodal agent in development for the treatment of major depression
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) has announced positive results from four pre-clinical animal studies with (vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other health agencies for the treatment of major depression.
AstraZeneca issues update on accelerated oncology pipeline
- Details
- Category: AstraZeneca
AstraZeneca today announced that it will be moving three of its cancer compounds forward to Phase III clinical development. As set out at its Investor Day in March, oncology is one of the company's core therapy areas and accelerating the development of a number of new molecular entities in its pipeline is a strategic priority.
GSK and Save the Children form unique partnership to save the lives of one million children
- Details
- Category: GlaxoSmithKline
An ambitious new partnership to save the lives of a million of the poorest children in the world has been launched by GSK and Save the Children. This unique collaboration will see the two organisations work together in a very different way, sharing expertise, resources, reach and influence to tackle some of the leading causes of childhood deaths.
Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis
- Details
- Category: Novartis
Novartis announced that the US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older. Ilaris is the first interleukin-1 beta (IL-1 beta) inhibitor approved for SJIA and the only treatment approved specifically for SJIA that is given as a once-monthly subcutaneous injection[1].
Amgen and Zhejiang Beta Pharma announce planned joint venture in China
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the Chinese market. Together, Amgen and Zhejiang Beta Pharma aim to quickly and efficiently deliver Vectibix to patients in China.
Boehringer Ingelheim joins Structural Genomics Consortium
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has joined the Structural Genomics Consortium (SGC). The consortium intends to promote research into protein structures and epigenetics that could pave the way for the development of novel therapies for previously uncurable diseases. As a member of the SGC, Boehringer Ingelheim will help fund precompetitive drug research aimed at bringing new, more effective medicines to patients faster.
Real-world data at ARVO highlight transformational outcomes seen with Lucentis®
- Details
- Category: Novartis
Novartis has reported that new data with the eye drug Lucentis® (ranibizumab), first licensed in June 2006, is highlighted in a total of 209 abstracts at the 2013 Association for Research in Vision and Ophthalmology (ARVO) annual meeting this week.
More Pharma News ...
- Bristol-Myers Squibb and Pfizer announce publication of ARISTOTLE subanalysis in Circulation
- Funding boost for GSK's open innovation research into diseases affecting the developing world
- Lundbeck is well on track to deliver on guidance for 2013
- Bayer: Life Sciences off to a good start in anniversary year
- Bristol-Myers Squibb reports first quarter 2013 financial results
- AstraZeneca first quarter results 2013
- Novartis delivered solid performance in the first quarter